Literature DB >> 8418305

Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas.

A De Chiara1, A T'Ang, T J Triche.   

Abstract

BACKGROUND: Alveolar and embryonal rhabdomyosarcomas are soft-tissue tumors that occur mainly in childhood. The more aggressive alveolar subtype has been found to possess a characteristic chromosomal abnormality located near the retinoblastoma susceptibility gene (RB1). RB1 is a tumor suppressor gene implicated in the development of retinoblastoma and other, unrelated malignancies, especially osteogenic sarcomas and other second malignancies in retinoblastoma survivors.
PURPOSE: The goals of our study were (a) to determine whether abnormalities of RB1 occur routinely in sporadic rhabdomyosarcomas, as reported for other sporadic malignancies, especially bone and soft-tissue sarcomas of adulthood; and (b) to assess differences in the functional status of the gene in embryonal and alveolar rhabdomyosarcomas that might explain the differing clinical aggressiveness of these two variants.
METHODS: Analyses of messenger RNA (mRNA) and protein expression and immunohistochemical studies were performed on 11 rhabdomyosarcoma cell lines from patients with no family history of retinoblastoma, and RB1 protein expression was studied by immunoprecipitation in primary tumor biopsy tissue from 18 patients with sporadic rhabdomyosarcoma (five embryonal and 13 alveolar).
RESULTS: The RB1 gene appears to be normal in structure, expression, and function and is comparably phosphorylated in both forms of childhood rhabdomyosarcoma. Normal-size RB1 mRNA was present in all rhabdomyosarcomas, whereas clearly abnormal expression was documented in the controls, as expected: mRNA transcripts were truncated in Y79 retinoblastoma and absent in DU4475 breast carcinoma. In addition, immunoprecipitation with antibody to RB1 protein indicated the presence of normal RB1 protein in all rhabdomyosarcomas.
CONCLUSIONS: These findings are distinct from those for other adult asarcomas, in which RB1 expression frequently is reported as abnormal. They are particularly surprising in view of the high incidence of RB1 abnormalities in osteosarcoma, the bone tumor most associated with retinoblastoma. The etiology and biologic behavior of rhabdomyosarcoma are, thus, unlikely to be dependent on RB1 mutations. IMPLICATIONS: The findings reported here clearly imply that the RB1 gene is structurally and functionally normal in childhood rhabdomyosarcoma. Other, as yet unidentified, genetic defects are apparently etiologic in this particular sarcoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418305     DOI: 10.1093/jnci/85.2.152

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

Review 1.  Developmental origins of fusion-negative rhabdomyosarcomas.

Authors:  Ken Kikuchi; Brian P Rubin; Charles Keller
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

2.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma.

Authors:  Brian P Rubin; Koichi Nishijo; Hung-I Harry Chen; Xiaolan Yi; David P Schuetze; Ranadip Pal; Suresh I Prajapati; Jinu Abraham; Benjamin R Arenkiel; Qing-Rong Chen; Sean Davis; Amanda T McCleish; Mario R Capecchi; Joel E Michalek; Lee Ann Zarzabal; Javed Khan; Zhongxin Yu; David M Parham; Frederic G Barr; Paul S Meltzer; Yidong Chen; Charles Keller
Journal:  Cancer Cell       Date:  2011-02-15       Impact factor: 31.743

Review 3.  Mechanisms of impaired differentiation in rhabdomyosarcoma.

Authors:  Charles Keller; Denis C Guttridge
Journal:  FEBS J       Date:  2013-07-31       Impact factor: 5.542

4.  Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.

Authors:  A P Dei Tos; S Piccinin; C Doglioni; T Vukosavljevic; T Mentzel; M Boiocchi; C D Fletcher
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

5.  Tumor suppressor genes and related molecules in leiomyosarcoma.

Authors:  A P Dei Tos; R Maestro; C Doglioni; S Piccinin; D D Libera; M Boiocchi; C D Fletcher
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Molecular approaches to sarcoma therapy.

Authors:  R J Olsen; S R Tarantolo; S H Hinrichs
Journal:  Sarcoma       Date:  2002

7.  Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma.

Authors:  Ken Kikuchi; Eri Taniguchi; Hung-I Harry Chen; Matthew N Svalina; Jinu Abraham; Elaine T Huang; Koichi Nishijo; Sean Davis; Christopher Louden; Lee Ann Zarzabal; Olivia Recht; Ayeza Bajwa; Noah Berlow; Mònica Suelves; Sherrie L Perkins; Paul S Meltzer; Atiya Mansoor; Joel E Michalek; Yidong Chen; Brian P Rubin; Charles Keller
Journal:  Skelet Muscle       Date:  2013-11-25       Impact factor: 4.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.